{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:42:18Z","timestamp":1768462938789,"version":"3.49.0"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>Glaucoma, characterized by chronic and progressive degeneration of retinal ganglion cells leading to a gradual decline in the visual field, poses a significant challenge in eye care delivery. Optometrists play a vital role in detecting and managing glaucoma. This study aims to determine how Ghanaian optometrists manage ocular adverse reactions (OADRs) in patients using antiglaucoma medications. A cross-sectional survey was conducted among 139 licensed optometrists using a pre-tested, semi-structured questionnaire. Data collected included socio-demographic characteristics, reported adverse reactions, and awareness of reporting or management protocols. Descriptive and inferential statistics were performed using SPSS version 25.0. Participants had a mean age of 31.6\u2009\u00b1\u20095.5 years and an average practice experience of 5.6\u2009\u00b1\u20094.5 years. Most respondents were female (71.2%), with 36.7% practicing in Greater Accra and 32.0% in private facilities. Nearly all participants (92.8%) reported encountering OADRs to AGMs. The most common symptoms were red eyes (36.0%), stinging (26.1%), burning sensation (25.4%), and itching (8.8%), while clinical signs included conjunctival hyperemia (45.5%), tear film deficiency (26.0%), and iris pigmentation changes (9.8%). Latanoprost (32.2%), timolol (23.7%), travoprost (17.6%), and brimonidine (10.2%) were the medications most frequently associated with these reactions. Optometrists primarily managed cases by switching to alternative medications (41.0%) or adjusting dosage and frequency (9.7%). However, 77.7% reported having no knowledge of existing protocols, and confidence in managing OADRs was moderately low (mean\u2009=\u20092.67\u2009\u00b1\u20090.49 on a 5-point scale). No significant association was found between OADR reporting and either age (p\u2009=\u20090.616) or years of practice (p\u2009=\u20090.974). These findings highlight that although OADRs are common in glaucoma management, optometrists in Ghana often lack standardized protocols and report low confidence in handling such cases. Targeted professional development and refresher training are needed to strengthen OADRs recognition, reporting, and management, ultimately improving patient eye care.<\/jats:p>","DOI":"10.1371\/journal.pgph.0004251","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:16Z","timestamp":1760031976000},"page":"e0004251","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Management of ocular adverse reactions to antiglaucoma medications\u2013Survey of optometrists in Ghana"],"prefix":"10.1371","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-1566","authenticated-orcid":true,"given":"Mohammed","family":"Abdul-Kabir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9043-7107","authenticated-orcid":true,"given":"Prince","family":"Mintah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9820-7028","authenticated-orcid":true,"given":"Michael Kwesi","family":"Asante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1680-5247","authenticated-orcid":true,"given":"James","family":"Forson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes","family":"Oppong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Anin","family":"Odame","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6135-7111","authenticated-orcid":true,"given":"Gabriel Kwaku","family":"Agbeshie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0693-2290","authenticated-orcid":true,"given":"Stephanie","family":"Obeng-Inkoom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"1","key":"pgph.0004251.ref001","first-page":"73","article-title":"Neurodegeneration and Neuroprotection in Glaucoma","volume":"89","author":"AC Gauthier","year":"2016","journal-title":"Yale J Biol Med"},{"issue":"2","key":"pgph.0004251.ref002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.preteyeres.2011.11.002","article-title":"The molecular basis of retinal ganglion cell death in glaucoma","volume":"31","author":"M Almasieh","year":"2012","journal-title":"Prog Retin Eye Res"},{"issue":"11","key":"pgph.0004251.ref003","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Y-C Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"11","key":"pgph.0004251.ref004","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"S Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"issue":"2","key":"pgph.0004251.ref005","first-page":"55","article-title":"Prevalence of blindness in people over 40 years in the volta region of ghana","volume":"39","author":"JP Guzek","year":"2005","journal-title":"Ghana Med J"},{"issue":"2","key":"pgph.0004251.ref006","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/00055735-200304000-00006","article-title":"Collaborative normal tension glaucoma study","volume":"14","author":"Normal Tension Glaucoma Study","year":"2003","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"pgph.0004251.ref007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/ICU.0b013e32834f1887","article-title":"What\u2019s new in laser treatment for glaucoma?","volume":"23","author":"JJ Meyer","year":"2012","journal-title":"Curr Opin Ophthalmol"},{"issue":"4","key":"pgph.0004251.ref008","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/mja2.50020","article-title":"Current management of glaucoma","volume":"210","author":"J Lusthaus","year":"2019","journal-title":"Med J Aust"},{"issue":"8","key":"pgph.0004251.ref009","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/sj.eye.6701674","article-title":"First-choice treatment preferences for primary open-angle glaucoma in the United Kingdom","volume":"19","author":"HDR McKee","year":"2005","journal-title":"Eye (Lond)"},{"issue":"4","key":"pgph.0004251.ref010","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.eye.6701515","article-title":"Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population","volume":"19","author":"R Bhatt","year":"2005","journal-title":"Eye (Lond)"},{"issue":"1","key":"pgph.0004251.ref011","doi-asserted-by":"crossref","DOI":"10.4081\/dts.2014.5278","article-title":"Self-reported adverse reactions associated with topical ophthalmic medication use: a cross-sectional survey","volume":"4","author":"S Kyei","year":"2014","journal-title":"Drugs Ther Studies"},{"issue":"8","key":"pgph.0004251.ref012","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bjo.85.8.897","article-title":"Blindness in Africa: present situation and future needs","volume":"85","author":"S Lewallen","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"pgph.0004251.ref013","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/cxo.12291","article-title":"A cross-sectional survey of optometrists and optometric practices in Ghana","volume":"98","author":"SB Boadi-Kusi","year":"2015","journal-title":"Clin Exp Optom"},{"issue":"3","key":"pgph.0004251.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/S2542-5196(21)00351-X","article-title":"Advancing the Sustainable Development Goals through improving eye health: a scoping review","volume":"6","author":"JH Zhang","year":"2022","journal-title":"Lancet Planet Health"},{"key":"pgph.0004251.ref015","volume-title":"Population and Housing Census: Population of Regions and Districts","author":"G Ghana","year":"2021"},{"issue":"1","key":"pgph.0004251.ref016","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s12886-023-03083-0","article-title":"Profiling and factors associated with glaucoma diagnostic practice in sub-Saharan Africa-a cross sectional study of Nigerian and Ghanaian optometrists","volume":"23","author":"S Ocansey","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"pgph.0004251.ref017","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2147\/OPTH.S44708","article-title":"Managing adverse effects of glaucoma medications","volume":"8","author":"K Inoue","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"56","key":"pgph.0004251.ref018","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.14260\/Jemds\/2017\/910","article-title":"Impact of adverse drug reactions of topical anti-glaucoma medications on the vision-related quality of life in primary open angle glaucoma","volume":"6","author":"N Sidhan","year":"2017","journal-title":"jemds"},{"issue":"3","key":"pgph.0004251.ref019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jtos.2018.03.002","article-title":"Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye","volume":"16","author":"ABC Wong","year":"2018","journal-title":"Ocul Surf"},{"issue":"4","key":"pgph.0004251.ref020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4103\/nmj.NMJ_116_19","article-title":"Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface","volume":"61","author":"OO Awe","year":"2020","journal-title":"Niger Med J"},{"key":"pgph.0004251.ref021","doi-asserted-by":"crossref","first-page":"696328","DOI":"10.1155\/2013\/696328","article-title":"How ocular surface disease impacts the glaucoma treatment outcome","volume":"2013","author":"S Ka\u0161telan","year":"2013","journal-title":"Biomed Res Int"},{"key":"pgph.0004251.ref022","doi-asserted-by":"crossref","first-page":"234157","DOI":"10.1155\/2015\/234157","article-title":"Analysis of Factors Affecting Patients\u2019 Compliance to Topical Antiglaucoma Medications in Egypt as a Developing Country Model","volume":"2015","author":"NB Abu Hussein","year":"2015","journal-title":"J Ophthalmol"},{"issue":"18","key":"pgph.0004251.ref023","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1021\/jm9608725","article-title":"New approaches to antiglaucoma therapy","volume":"40","author":"MF Sugrue","year":"1997","journal-title":"J Med Chem"},{"key":"pgph.0004251.ref024","doi-asserted-by":"crossref","first-page":"106315","DOI":"10.1016\/j.ejps.2022.106315","article-title":"Trends in development and quality assessment of pharmaceutical formulations - F2\u03b1 analogues in the glaucoma treatment","volume":"180","author":"K Asendrych-Wicik","year":"2023","journal-title":"Eur J Pharm Sci"},{"key":"pgph.0004251.ref025","article-title":"Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population","author":"R Bhatt","year":"2005","journal-title":"Nature"},{"issue":"4","key":"pgph.0004251.ref026","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.4103\/IJO.IJO_2782_22","article-title":"A review on drug-induced dry eye disease","volume":"71","author":"KW Kam","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"pgph.0004251.ref027","doi-asserted-by":"crossref","DOI":"10.1080\/08820538.2022.2094714","article-title":"Ocular surface disease and anti-glaucoma medications: various features, diagnosis, and management guidelines","volume-title":"Seminars in Ophthalmology","author":"S Andole","year":"2023"},{"issue":"3","key":"pgph.0004251.ref028","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1080\/15569527.2020.1787435","article-title":"Influence of timolol, benzalkonium-preserved timolol, and benzalkonium-preserved brimonidine on oxidative stress biomarkers in the tear film","volume":"39","author":"L Sedlak","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"issue":"11","key":"pgph.0004251.ref029","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1080\/17425255.2016.1209481","article-title":"Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK)","volume":"12","author":"A Aguayo Bonniard","year":"2016","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"pgph.0004251.ref030","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1755-3768.2008.01250.x","article-title":"Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma","volume":"86","author":"C Baudouin","year":"2008","journal-title":"Acta Ophthalmol"},{"key":"pgph.0004251.ref031","volume-title":"Antiglaucoma drugs: The role of preservative-free formulations","author":"A Bagnis","year":"2011"},{"key":"pgph.0004251.ref032","article-title":"Effect of chronic anti-glaucoma medications and trabeculectomy on tear osmolarity","author":"S Lee","year":"2013","journal-title":"Nature"},{"issue":"7","key":"pgph.0004251.ref033","article-title":"Effect of patient-centered communication training on discussion and detection of nonadherence in glaucoma","volume":"117","author":"SR Hahn","year":"2010","journal-title":"Ophthalmology"},{"key":"pgph.0004251.ref034","doi-asserted-by":"crossref","first-page":"100191","DOI":"10.1016\/j.ijans.2020.100191","article-title":"Evaluating the knowledge, attitudes and practices of healthcare workers towards adverse drug reaction reporting at a public tertiary hospital in Johannesburg","volume":"12","author":"Y Gordhon","year":"2020","journal-title":"International Journal of Africa Nursing Sciences"},{"issue":"4","key":"pgph.0004251.ref035","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.3390\/ijerph20043725","article-title":"Severity and Management of Adverse Drug Reactions Reported by Patients and Healthcare Professionals: A Cross-Sectional Survey","volume":"20","author":"W Srisuriyachanchai","year":"2023","journal-title":"Int J Environ Res Public Health"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004251","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:46:23Z","timestamp":1760031983000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004251"}},"subtitle":[],"editor":[{"given":"Julia","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0004251","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]}}}